Key result
Acute myocardial infarction was associated with reduced platelet prostacyclin receptor binding capacity compared to controls.
Why the study?
Reduced platelet responsiveness to prostacyclin reported in vitro in coronary artery disease patients was thought to predispose toward coronary thrombosis and vasospasm, prompting investigation of specific prostacyclin binding to intact platelets and postreceptor responses.
Does acute myocardial infarction or stable angina alter specific platelet prostacyclin binding capacity and cyclic AMP accumulation compared to control subjects?
Case-Control (n=52)
Does acute myocardial infarction or stable angina alter specific platelet prostacyclin binding capacity and cyclic AMP accumulation compared to control subjects?
Patients with acute myocardial infarction, unlike those with stable angina, exhibit significantly reduced platelet prostacyclin receptor binding capacity and impaired postreceptor cyclic AMP synthesis.
Answers are grounded in this paper and cite their sources.
Reduced prostacyclin receptor binding in AMI may impair antiaggregatory responses; hypothesis-generating for pathway modulation in ACS.
Reduced responsiveness of platelets to prostacyclin, reported in vitro in patients with coronary artery disease, has been thought to be a factor predisposing toward coronary thrombosis and vasospasm as a result of enhanced in vivo release of cyclic endoperoxides and thromboxane A2 by the platelets. In this study, specific binding of prostacyclin to intact platelets was determined in patients with coronary artery disease by direct binding studies using 9-3H-prostacyclin sodium salt. In addition, the inhibitory effect of prostacyclin on primary aggregation induced by adenosine diphosphate and cyclic adenosine monophosphate (cyclic AMP) accumulation stimulated by prostacyclin was examined. Twenty patients with angiographically documented coronary artery disease and stable angina, 8 patients with acute myocardial infarction, 14 healthy volunteers and 10 patients with normal angiograms were studied. In patients with stable angina, binding capacity and affinity of platelet prostacyclin binding sites and prostacyclin-induced cyclic AMP accumulation were not different from those of control subjects. In patients with acute myocardial infarction, however, binding capacity of platelet prostacyclin receptors was significantly reduced (0.69 +/- 0.45 versus 1.35 +/- 0.37 pmol/10(9) platelets, p = 0.001) and the postreceptor response, represented by platelet responsiveness to prostacyclin and prostacyclin-induced cyclic AMP synthesis, was impaired. Because all patients with myocardial infarction were receiving intravenous heparin and nitroglycerin, which might interfere with platelet prostacyclin binding, competition experiments were performed in vitro. Neither heparin (3 to 250 IU/ml) nor nitroglycerin (0.8 to 22 microM) displaced specifically bound 9-3H-prostacyclin. L-Epinephrine in concentrations up to 10 microM also exhibited no competition with specific platelet prostacyclin binding.(ABSTRACT TRUNCATED AT 250 WORDS)
No takes yet. Share an insight, caveat, or question.
Jaschonek et al. (1986) conducted a case-control in Coronary artery disease and acute myocardial infarction (n=52). Acute myocardial infarction / Coronary artery disease vs. Control subjects (healthy volunteers and patients with normal angiograms) was evaluated on Binding capacity of platelet prostacyclin receptors (pmol/10^9 platelets) (p=0.001). Acute myocardial infarction was associated with reduced platelet prostacyclin receptor binding capacity compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: